Response to Frederic Bretzner et al. "Target populations for first-in-human embryonic stem cell research in spinal cord injury"

Cell Stem Cell. 2011 May 6;8(5):476-8. doi: 10.1016/j.stem.2011.04.008.

Abstract

We address concerns raised in this issue by Bretzner et al. (2011) by explaining the rationale for including subjects with subacute, neurologically complete spinal cord injuries in the Phase 1 trial of GRNOPC1. We also present elements of the informed consent process that minimize the likelihood of therapeutic misconception.

Publication types

  • Comment

MeSH terms

  • Animals
  • Biomedical Research
  • Clinical Trials, Phase I as Topic
  • Consent Forms / ethics*
  • Consent Forms / legislation & jurisprudence
  • Health Care Rationing
  • Humans
  • Knowledge Bases
  • Models, Animal
  • Patient Rights
  • Patient Selection / ethics*
  • Recovery of Function
  • Risk Assessment
  • Spinal Cord Injuries / epidemiology
  • Spinal Cord Injuries / therapy*
  • Treatment Outcome